Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy.

被引：0
|
作者：
Ghidini, Michele
Hahne, Jens Claus
Senti, Chiara
Tomasello, Gianluca
Ratti, Margherita
Heide, Timon
Garrone, Ornella
Cortellini, Alessio
Passalacqua, Rodolfo
Valeri, Nicola
机构：
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Med Oncol, Milan, Italy
[2] Inst Canc Res, London, England
[3] Hosp Cremona, Div Med Oncol, ASST Cremona, Cremona, Italy
[4] Human Technopole, Milan, Italy
[5] Imperial Coll London, Div Surg & Canc, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
175
引用
收藏
页码：175 / 175
页数：1
相关论文
共 50 条
  • [21] Prospective analysis of CEA, circulating DNA (cDNA) and circulating tumor cells (CTC) kinetics in patients (pts) treated for a metastatic colorectal cancer (mCRC).
    Sefrioui, David
    Sarafan-Vasseur, Nasrin
    Toure, Emmanuel
    Delacour, Julien
    Ziegler, Frederic
    Thill, Caroline
    Gangloff, Alice
    Blanchard, France
    Beaussire, Ludivine
    Leporrier, Karine Bouhier
    Galais, Marie-Pierre
    Perdrix, Anne
    Clatot, Florian
    Jardin, Fabrice
    Sabourin, Jean-Christophe
    Frebourg, Thierry
    Michel, Pierre
    Di Fiore, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Coi regimen (capecitabine, oxaliplatin, irinotecan) as front-line combination in metastatic colorectal cancer patients (PTS)
    Ferrario, E.
    Di Bartolomeo, M.
    Buzzoni, R.
    Del Vecchio, M.
    Beretta, E.
    Di Marco, R.
    Paleari, D.
    Gevorgyan, A.
    Bajetta, E.
    ANNALS OF ONCOLOGY, 2005, 16 : 41 - 41
  • [23] Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer
    Lee, Dae-Won
    Lim, Yoojoo
    Kim, Hwang-Phill
    Kim, Su Yeon
    Roh, Hanseong
    Kang, Jun-Kyu
    Lee, Kyung-Hun
    Kim, Min Jung
    Ryoo, Seung-Bum
    Park, Ji Won
    Jeong, Seung-Yong
    Park, Kyu Joo
    Kang, Gyeong Hoon
    Han, Sae-Won
    Kim, Tae-You
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 927 - 938
  • [24] Circulating tumour DNA (ctDNA) as a prognostic biomarker in patients (pts) with refractory metastatic colorectal cancer (mCRC) receiving TAS102 with or without bevacizumab
    Saoudi Gonzalez, N.
    Navarro Garces, V.
    Salva Ballabrera, F.
    Ros Montana, F. J.
    Baraibar Argota, I.
    Rodriguez Castells, M.
    Vaghi, C.
    Garcia Rodriguez, A.
    Alcaraz, A.
    Comas, R.
    Dienstmann, R.
    Tabernero, J.
    Vivancos, A.
    Elez Fernandez, M. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S58 - S59
  • [25] Front-line use of FOLFOXIRI plus bevacizumab and subsequent therapies in metastatic colorectal cancer (mCRC).
    Barzi, Afsaneh
    Lunacsek, Orsolya
    Pisa, Federica
    Pan, Xiaoyun
    Ostojic, Helene
    Vassilev, Zdravko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 45 - 45
  • [26] RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies n patients with metastatic colorectal cancer (mCRC)
    Sunakawa, Y.
    Nakamura, M.
    Ishizaki, M.
    Kataoka, M.
    Satake, H.
    Kitazono, M.
    Yanagisawa, H.
    Kawamoto, Y.
    Kuramochi, H.
    Ohori, H.
    Nakamura, M.
    Takahashi, K.
    Maeda, F.
    Komeno, C.
    Takeuchi, M.
    Fujii, M.
    Yoshino, T.
    Ichikawa, W.
    Tsuji, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 114 - 114
  • [27] Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).
    Pusztai, Lajos
    Chung, Jon
    Young, Lauren
    Schrock, Alexa Betzig
    Hartmaier, Ryan
    Frampton, Garrett Michael
    Gay, Laurie M.
    Stephens, Phil
    Miller, Vincent A.
    Ali, Siraj Mahamed
    Ross, Jeffrey S.
    Vahdat, Linda T.
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Clinical utility of serial circulating tumor DNA (ctDNA) to identify acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer (mCRC).
    Loree, Jonathan M.
    Bubie, Adrian
    Eluri, Madhulika
    Parseghian, Christine Megerdichian
    Overman, Michael J.
    Zhang, Nicole
    Drusbosky, Leylah
    Kopetz, Scott
    Raghav, Kanwal Pratap Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 158 - 158
  • [29] Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial
    Raghav, Kanwal Pratap Singh
    Ou, Fang-Shu
    Venook, Alan P.
    Innocenti, Federico
    Sun, Ryan
    Lenz, Heinz-Josef
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [30] Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial
    Santos Vivas, C.
    Vidal Barrull, J.
    Fernandez Rodriguez, C.
    Salva Ballabrera, F.
    Alonso-Orduna, V.
    Garcia-Carbonero, R.
    Losa, F.
    Tarazona Llavero, N.
    Safont Aguileria, M. J.
    Rivera Herrero, F.
    Layos Romero, L.
    Ortiz Morales, M. J.
    Salud, A.
    Alcaide-Garcia, J.
    Paez, D.
    Hernandez-Yague, X.
    Alvarez Gallego, R.
    Vera, R.
    Bellosillo Paricio, B.
    Montagut Viladot, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S433 - S434
12345